RxSight (RXST) Liabilities and Shareholders Equity (2020 - 2026)
RxSight filings provide 6 years of Liabilities and Shareholders Equity readings, the most recent being $311.8 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 2.12% to $311.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 11.16% increase, with the full-year FY2025 number at $311.8 million, down 2.12% from a year prior.
- Liabilities and Shareholders Equity hit $311.8 million in Q4 2025 for RxSight, up from $308.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $318.6 million in Q4 2024 to a low of $94.9 million in Q2 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $195.3 million (2023), compared with a mean of $224.4 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: surged 91.43% in 2021 and later dropped 23.57% in 2022.
- RxSight's Liabilities and Shareholders Equity stood at $192.7 million in 2021, then dropped by 22.08% to $150.2 million in 2022, then rose by 21.57% to $182.5 million in 2023, then surged by 74.51% to $318.6 million in 2024, then decreased by 2.12% to $311.8 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $311.8 million (Q4 2025), $308.5 million (Q3 2025), and $309.0 million (Q2 2025) per Business Quant data.